ONC Supplement November 2011 Intro
The goal of this supplement is to present a comprehensive overview of the major current and emerging treatment options for patients with relapsed and/or refractory multiple myeloma, with particular focus on proteasome inhibitors and immunomodulatory drugs, along with other emerging agents (eg, histone deacetylase inhibitors, heat shock protein inhibitors, and monoclonal antibodies). As the treatment landscape has evolved, it has become readily apparent that the available therapies have different tolerability profiles depending on patient and disease characteristics.
The goal of this supplement is to present a comprehensive overview of the major current and emerging treatment options for patients with relapsed and/or refractory multiple myeloma, with particular focus on proteasome inhibitors and immunomodulatory drugs, along with other emerging agents (eg, histone deacetylase inhibitors, heat shock protein inhibitors, and monoclonal antibodies). As the treatment landscape has evolved, it has become readily apparent that the available therapies have different tolerability profiles depending on patient and disease characteristics.
The supplement and associated publication costs were funded by Onyx Pharmaceuticals
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
!["[These] data provide framework to assist in patient counseling and optimizing selection," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fafc4e7af61f986692735b0d673f3933a45f75fc2-2249x2250.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[These] data provide framework to assist in patient counseling and optimizing selection,\" according to the study authors.")
